PPIDT00403
Drug Information
| Name | Relatlimab |
|---|---|
| Sequence | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG |
| DrugBank_ID | DB14851 |
| Type | biotech |
| Indication | Relatlimab is indicated in combination with [nivolumab], in the combination product Opdualag, for the treatment of adult and pediatric patients ≥12 years old with unresectable or metastatic melanoma.[L41265] In Canada and the EU, it is specifically indicated as a first-line treatment,[L50001,L50011] and the EU adds an additional requirement that tumor cell PD-L1 expression be < 1%.[L50011] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous |
|
| Injection, solution, concentrate | Intravenous |
|
| Solution | Intravenous |
|